- Home
- NFE vs ALEC Comparison
NFE vs ALEC Comparison
Compare NFE & ALEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NFE | ALEC |
|---|---|---|
| Founded | 2014 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 324.4M | 268.2M |
| IPO Year | 2018 | 2019 |
Fundamental Metrics
Financial Performance| Metric | NFE | ALEC |
|---|---|---|
| Price | $0.69 | $2.16 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $5.50 | $4.83 |
| AVG Volume (30 Days) | ★ 6.1M | 488.8K |
| Earning Date | 04-13-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,504,037,000.00 | $21,045,000.00 |
| Revenue This Year | $110.34 | $2.03 |
| Revenue Next Year | $3.54 | $29.87 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.56 | $1.09 |
| 52 Week High | $4.96 | $3.40 |
Technical Indicators
Market Signals| Indicator | NFE | ALEC |
|---|---|---|
| Relative Strength Index (RSI) | 46.34 | 42.30 |
| Support Level | $0.59 | $1.91 |
| Resistance Level | $0.77 | $2.62 |
| Average True Range (ATR) | 0.07 | 0.15 |
| MACD | 0.01 | -0.04 |
| Stochastic Oscillator | 25.87 | 16.55 |
Price Performance
Historical ComparisonAbout NFE New Fortress Energy Inc.
New Fortress Energy Inc is an integrated gas-to-power company. Its business model spans the entire production and delivery chain from natural gas procurement and liquefaction to logistics, shipping, terminals, and conversion or development of a natural gas-fired generation. It has invested in floating, liquefied natural gas vessels to lower the cost of acquiring gas while securing a long-term supply for its terminals. Its segments include Terminals & Infrastructure, and Ships. It generates the majority of its revenue from the Terminals & Infrastructure segment.
About ALEC Alector Inc.
Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.